Erratum: Effect of GLP ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: A randomized, placebo‐controlled trial

CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials

Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693 · see citing works

Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality

McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280 · see citing works

Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’

The Reference Values for Arterial Stiffness' Collaboration (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq165 · Cited by 2,085 · see citing works

Prevalence of obesity in the United States, 2009-2010.

Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2012) · PubMed · Cited by 2,070 · see citing works

A Systematic Review of Mortality in Schizophrenia: Is the Differential Mortality Gap Worsening Over Time?

Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065 · see citing works

Brain Dopamine and Reward

Wise, R. A., & Rompre, P.-P. (1989) · Annual Review of Psychology · doi:10.1146/annurev.ps.40.020189.001203 · Cited by 1,968 · see citing works

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · see citing works

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · see citing works

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Buchanan, R., Kreyenbuhl, J., Kelly, D., Noel, J. M., Boggs, D., Fischer, B., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia bulletin · doi:10.1093/schbul/sbp116 · Cited by 844 · see citing works

Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden

Nordentoft, M., Wahlbeck, K., Hällgren, J., Westman, J., Ösby, U., Alinaghizadeh, H., Gissler, M., & Laursen, T. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055176 · Cited by 778 · see citing works

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · see citing works

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study

Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565 · see citing works

Obesity among those with mental disorders: a National Institute of Mental Health meeting report.

Allison, D., Newcomer, J., Dunn, A., Blumenthal, J., Fabricatore, A., Daumit, G., Cope, M., Riley, W., Vreeland, B., Hibbeln, J., et al. (2009) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2008.11.020 · Cited by 411 · see citing works

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

Buse, J. B., Drucker, D. J., Taylor, K., Kim, T., Walsh, B., Hu, H., Wilhelm, K., TRAUTMANN, M. E., Shen, L. Z., Porter, L. E., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1914 · Cited by 357 · see citing works

Relation of obesity to consummatory and anticipatory food reward

Stice, E. M., Spoor, S. T. P., Ng, J., & Zald, D. H. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.03.020 · Cited by 289 · see citing works

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial

Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250 · see citing works

Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis

Maayan, L. A., Vakhrusheva, J., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.21 · Cited by 230 · see citing works

Interventions to reduce weight gain in schizophrenia

Faulkner, G., Cohn, T. A., & Remington, G. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005148.pub2 · Cited by 226 · see citing works

Oscillometric estimation of central blood pressure

Weiß, W. W., Gohlisch, C., Harsch-Gladisch, C., Tölle, M., Zidek, W., & van der Giet, M. (2012) · Blood Pressure Monitoring · doi:10.1097/mbp.0b013e328353ff63 · Cited by 208 · see citing works

Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?

Albrechtsen, N. J. W., Hartmann, B., Veedfald, S., Windeløv, J. A., Plamboeck, A., Bojsen-Møller, K. N., Idorn, T., Feldt‐Rasmussen, B., Knop, F. K., Vilsbøll, T., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3283-z · Cited by 185 · see citing works

24-h ambulatory recording of aortic pulse wave velocity and central systolic augmentation: a feasibility study

Luzardo, L., Lujambio, I., Sottolano, M., da Rosa, A., Thijs, L., Noboa, O. A., Staessen, J. A., & Boggia, J. G. (2012) · Hypertension Research · doi:10.1038/hr.2012.78 · Cited by 149 · see citing works

Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder

Jarskog, L. F., Hamer, R. M., Catellier, D. J., Stewart, D. D., LaVange, L., Ray, N., Golden, L. H., Lieberman, J. A., Stroup, T. S., & for the METS Investigators (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12010127 · Cited by 145 · see citing works

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function

Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137 · see citing works

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

Fineman, M. S., Flanagan, S. D., Taylor, K., Aisporna, M., Shen, L. Z., Mace, K. F., Walsh, B., Diamant, M., Cirincione, B. B., Kothare, P. A., et al. (2010) · Clinical Pharmacokinetics · doi:10.2165/11585880-000000000-00000 · Cited by 135 · see citing works

Reference Values of Pulse Wave Velocity in Healthy People from an Urban and Rural Argentinean Population

Díaz, A., Galli, C., Tringler, M., Ramirez, A. J., & Fischer, E. I. C. (2014) · International Journal of Hypertension · doi:10.1155/2014/653239 · Cited by 129 · see citing works

The Role of Hypothalamic H1 Receptor Antagonism in Antipsychotic-Induced Weight Gain

He, M. X., Deng, C., & Huang, X. (2013) · CNS Drugs · doi:10.1007/s40263-013-0062-1 · Cited by 124 · see citing works

Blinding during data analysis and writing of manuscripts

Gøtzsche, P. C. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00263-4 · Cited by 123 · see citing works

Somatic Comorbidity in Schizophrenia: Some Possible Biological Mechanisms Across the Life Span

Dieset, I., Andreassen, O. A., & Haukvik, U. K. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw028 · Cited by 108 · see citing works

Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems

Mukundan, A., Faulkner, G., Cohn, T. A., & Remington, G. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006629.pub2 · Cited by 103 · see citing works

Effect of <scp>GLP</scp> ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: <scp>a</scp> randomized, placebo‐controlled trial

Ishøy, P. L., Knop, F. K., Broberg, B. V., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Glenthøj, B. Y., & Ebdrup, B. H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12795 · Cited by 102 · see citing works

Treatment of clozapine‐associated obesity and diabetes with exenatide in adults with schizophrenia: <scp>A</scp> randomized controlled trial ( <scp>CODEX</scp> )

Siskind, D. J., Russell, A. W., Gamble, C., Winckel, K., Mayfield, K., Hollingworth, S., Hickman, I., Siskind, V., & Kisely, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13167 · Cited by 98 · see citing works

Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels

Weston–Green, K., Huang, X., Lian, J., & Deng, C. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.09.003 · Cited by 97 · see citing works

Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis

Chiu, L., Chow, R., Popovic, M. M., Navari, R. M., Shumway, N. M., Chiu, N., Lam, H., Milakovic, M., Pasetka, M., Vuong, S., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3075-8 · Cited by 92 · see citing works

Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior

Anderberg, R. H., Anefors, C., Bergquist, F., Nissbrandt, H., & Skibicka, K. P. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.02.026 · Cited by 90 · see citing works

Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment

Nielsen, M. Ø., Rostrup, E., Wulff, S., Glenthoj, B. Y., & Ebdrup, B. H. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2582 · Cited by 76 · see citing works

Efficacy of behavioural interventions in managing atypical antipsychotic weight gain

Gabriele, J. M., Dubbert, P. M., & Reeves, R. R. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00570.x · Cited by 58 · see citing works

Obesity in Adults with Serious and Persistent Mental Illness: A Review of Postulated Mechanisms and Current Interventions

Megna, J. L., Schwartz, T. L., Siddiqui, U. A., & Herrera, M. (2011) · Annals of Clinical Psychiatry · doi:10.1177/104012371102300207 · Cited by 53 · see citing works

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits

Ebdrup, B. H., Knop, F. K., Ishøy, P. L., Rostrup, E., Fagerlund, B., Lublin, H., & Glenthøj, B. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-92 · Cited by 34 · see citing works

Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes

Ishøy, P. L., Knop, F. K., Vilsbøll, T., Glenthoj, B. Y., & Ebdrup, B. H. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12101344 · Cited by 28 · see citing works

Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients

Rasmussen, H., Ebdrup, B. H., Oranje, B., Pinborg, L. H., Knudsen, G. M., & Glenthoj, B. Y. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000777 · Cited by 27 · see citing works

Risk?benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting

Herrstedt, J. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.3.231 · Cited by 25 · see citing works

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol

Ishøy, P. L., Knop, F. K., Broberg, B. V., Baandrup, L., Fagerlund, B., Jørgensen, N. R., Andersen, U. B., Rostrup, E., Glenthoj, B. Y., & Ebdrup, B. H. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004158 · Cited by 24 · see citing works

Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-Treated Patients

Ebdrup, B. H., Knop, F. K., Madsen, A., Mortensen, H. B., Søgaard, B., Holst, J. J., Szecsi, P. B., & Lublin, H. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08820 · Cited by 21 · see citing works

Risk?benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting

Herrstedt, J. (2004) · Expert Opinion on Drug Safety · doi:10.1517/eods.3.3.231.31076 · Cited by 21 · see citing works

Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia.

Caravaggio, F., Hahn, M., Nakajima, S., Gerretsen, P., Remington, G., & Graff-Guerrero, A. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.06.011 · Cited by 17 · see citing works

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial

Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250 · see citing works

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans

Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231 · see citing works

Association between antipsychotic medication use and diabetes

Holt, R. I. G. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1220-8 · Cited by 162 · see citing works

Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis

Siskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13522 · Cited by 144 · see citing works

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series

Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., et al. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231165169 · Cited by 88 · see citing works

A Focused Review of the Metabolic Side-Effects of Clozapine

Yuen, J. W. Y., Kim, D. D., Procyshyn, R. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609240 · Cited by 92 · see citing works

Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics

Cernea, S., Dima, L., Correll, C. U., & Manu, P. (2020) · Drugs · doi:10.1007/s40265-020-01393-x · Cited by 74 · see citing works

One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients

Svensson, C. K., Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, C. T., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12982 · Cited by 66 · see citing works

Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review

Vasiliu, O. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12054 · Cited by 60 · see citing works

Effect of weight loss on blood pressure changes in overweight patients: A systematic review and meta‐analysis

Yang, S., Zhou, Z., Miao, H., & Zhang, Y. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14661 · Cited by 55 · see citing works

The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study

Ozeki, Y., Masaki, T., Kamata, A., Miyamoto, S., Yoshida, Y., Okamoto, M., Gotoh, K., & Shibata, H. (2022) · Medicines · doi:10.3390/medicines9090047 · Cited by 53 · see citing works

Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis

Yeh, T., Tsai, M.-C., Tsai, W.-H., Tu, Y., & Chien, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278685 · Cited by 51 · see citing works

Pharmacological interventions for prevention of weight gain in people with schizophrenia

Agarwal, S. M., Stogios, N., Ahsan, Z. A., Lockwood, J., Duncan, M. J., Takeuchi, H., Cohn, T. A., Taylor, V. H., Remington, G. J., Faulkner, G., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013337.pub2 · Cited by 47 · see citing works

The Management of Obesity in People with Severe Mental Illness: An Unresolved Conundrum

Holt, R. I. G. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000503835 · Cited by 42 · see citing works

Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

Sass, M. R., Danielsen, A. A., Köhler‐Forsberg, O., Storgaard, H., Knop, F. K., Nielsen, M. Ø., Sjödin, A. M., Mors, O. N., Correll, C. U., Ekstrøm, C. T., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068652 · Cited by 41 · see citing works

Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis

Khaity, A. M., Al-dardery, N. M., Albakri, K. A., Abdelwahab, O. A., Hefnawy, M. T., Yousef, Y. S. A. H., Taha, R. E. W., Swed, S., Hafez, W., Hurlemann, R., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1153648 · Cited by 35 · see citing works

The Potential Role of GLP-1 Agonists in Psychiatric Disorders: A Paradigm Shift in Mental Health Treatment

Gunturu, S. (2024) · Indian Journal of Psychological Medicine · doi:10.1177/02537176241246744 · Cited by 29 · see citing works

Brain insulin action: Implications for the treatment of schizophrenia

Agarwal, S. M., Kowalchuk, C., Castellani, L. N., Costa-Dookhan, K. A., Caravaggio, F., Asgariroozbehani, R., Chintoh, A. F., Graff‐Guerrero, A., & Hahn, M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.032 · Cited by 28 · see citing works

Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients

Lee, S. E., Lee, N. Y., Kim, S. H., Kim, K.-A., & Kim, Y. S. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113830 · Cited by 27 · see citing works

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Eriksson, R., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Knop, F. K., & Ebdrup, B. H. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00781 · Cited by 26 · see citing works

Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis

Kanagasundaram, P., Lee, J., Prasad, F., Costa-Dookhan, K. A., Hamel, L., Gordon, M., Remington, G. J., Hahn, M., & Agarwal, S. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.642403 · Cited by 26 · see citing works

Liraglutide for psychiatric disorders: clinical evidence and challenges

Camkurt, M. A., Lavagnino, L., Zhang, X. Y., & Teixeira, A. L. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2018-0031 · Cited by 27 · see citing works

Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial

Whicher, C. A., Price, H. C., Phiri, P., Rathod, S., Barnard-Kelly, K. D., Reidy, C., Thorne, K. I., Asher, C. J., Peveler, R., McCarthy, J., et al. (2019) · Trials · doi:10.1186/s13063-019-3689-5 · Cited by 24 · see citing works

Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Patoulias, D., Michailidis, T., Dimosiari, A., Fragakis, N., Tse, G., & Rizzo, M. (2023) · Biomedicines · doi:10.3390/biomedicines11030669 · Cited by 27 · see citing works

Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats

Horská, K., Kučerová, J., Dražanová, E., Karpíšek, M., Demlová, R., Kašpárek, T., & Kotolová, H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.003 · Cited by 20 · see citing works

Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study

Barnard-Kelly, K. D., Whicher, C. A., Price, H. C., Phiri, P., Rathod, S., Asher, C. J., Peveler, R., & Holt, R. I. G. (2022) · BMC Psychiatry · doi:10.1186/s12888-021-03666-5 · Cited by 22 · see citing works

The Obesity–Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients

Sfera, A., Osorio, C. P., Inderias, L., Parker, V., Price, A. I., & Cummings, M. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00020 · Cited by 18 · see citing works

Semaglutide is effective in type 2 diabetes and obesity with schizophrenia

Noda, K., Kato, T., Nomura, N., Sakai, M., Kubota, S., Hirose, T., Liu, Y., Takahashi, Y., Takao, K., Mizuno, M., et al. (2022) · Diabetology International · doi:10.1007/s13340-022-00590-1 · Cited by 15 · see citing works

Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence

Llach, C.-D., Badulescu, S., Tabassum, A., Shah, H., Gill, H., Le, G. H., Vieta, E., McIntyre, R. S., Rosenblat, J. D., & Mansur, R. B. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03261-0 · Cited by 15 · see citing works

Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness?

Namara, K. M., Alzubaidi, H., Murray, M., Samorinha, C., Dunbar, J., Versace, V. L., & Castle, D. J. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51701 · Cited by 7 · see citing works

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment

Grywińska, W. B., & Głowacka, A. (2023) · Postępy Psychiatrii i Neurologii · doi:10.5114/ppn.2023.132493 · Cited by 5 · see citing works

Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics

Ando, T., Hatada, K., Sata, M., Tachiki, H., Fukazawa, T., Kusumoto, S., Horie, I., Abiru, N., Matsumoto, S., & Kawakami, A. (2018) · Nagasaki University's Academic Output SITE (Nagasaki University) · doi:10.11343/amn.61.151 · Cited by 4 · see citing works

Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials

Srisurapanont, M., Suttajit, S., Likhitsathian, S., Suradom, C., & Maneeton, B. (2026) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174261422822 · Cited by 4 · see citing works

Managing glucose-related adverse events of antipsychotics is worth the effort

Fenton, C., & Kang, C. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-021-00856-9 · Cited by 1 · see citing works

‘No cognitive‐enhancing effect of GLP ‐1 receptor agonism in antipsychotic‐treated, obese patients with schizophrenia’: authors' response

Ebdrup, B. H., Ishøy, P. L., Fagerlund, B., Broberg, B. V., Bak, N., Knop, F. K., & Glenthoj, B. Y. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12795 · Cited by 1 · see citing works

Effect of <scp>GLP</scp> ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: <scp>a</scp> randomized, placebo‐controlled trial

Ishøy, P. L., Knop, F. K., Broberg, B. V., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Glenthøj, B. Y., & Ebdrup, B. H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12795 · Cited by 102 · see citing works

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol

Ishøy, P. L., Knop, F. K., Broberg, B. V., Baandrup, L., Fagerlund, B., Jørgensen, N. R., Andersen, U. B., Rostrup, E., Glenthoj, B. Y., & Ebdrup, B. H. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004158 · Cited by 24 · see citing works

SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity

Ishøy, P. L., Knop, F. K., Broberg, B. V., Bak, N. K., Andersen, U. B., Jørgensen, N. R., Fagerlund, B., Holst, J. J., Glenthoj, B. Y., & Ebdrup, B. H. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx024.017 · Cited by 2 · see citing works

Treatment of antipsychotic-associated

(2013)

No cognitive‐enhancing effect of GLP ‐1 receptor agonism in antipsychotic‐treated, obese patients with schizophrenia

Ishøy, P. L., Fagerlund, B., Broberg, B. V., Bak, N., Knop, F. K., Glenthoj, B. Y., & Ebdrup, B. H. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12711 · Cited by 54 · see citing works